Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata

November 01, 2023 12:05 PM AEDT | By Cision

Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata — Image source: Kalkine Media

Recent News

ASX ends higher as energy and tech stocks advance

ASX Penny Stocks Spotlight: Berkeley Energia And Two More To Consider

Top Picks Among ASX Dividend Stocks: DUI, GNG, and IGL

Why Macquarie says this ASX 200 mining stock could rocket 67% in a yea...

LONDON, Nov. 1, 2023 /PRNewswire/ -- Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be available in Q2 2024.

David Fleet, CEO of Soterios Pharma, said, "This represents an important milestone in the development of STS-01 as the first approved treatment for patients with mild-to-moderate alopecia areata. Whilst there are now options available for severe patients, there are still no approved treatments for patients with patchy disease – and yet they represent over half of the alopecia areata population and the quality-of-life impact can be devastating. We are developing STS-01 as an effective and convenient topical treatment to address this unmet need."

The randomised, placebo-controlled Phase II trial is evaluating the safety and efficacy of STS-01 applied for 6 months. A total of 158 participants have been randomised to receive one of four doses of STS-01 or placebo, with effect being measured based on improvement in the SALT score.

About Soterios Pharma
Soterios Pharma is a UK-based clinical-stage life sciences company, which is focused on developing and commercialising medicines for dermatology diseases with major unmet needs. The company's approach leverages deep scientific knowledge of medical dermatology to identify 'de-risked' opportunities to improve patients' lives. https://www.soteriospharma.com

About STS-01
The product builds on a mechanism with a well-established safety profile in dermatology, and works through modulating the inflammatory response and the proliferation of T-cells by disruption of the signalling pathways. There is extensive pre-clinical and clinical evidence to support its efficacy and safety profile in alopecia areata. The product is being developed as a topical treatment for mild / moderate alopecia areata (SALT score <50), which represents over half of the 700,000 AA patients in the US.

Soterios Pharma contacts:
Mark Brimble
[email protected]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.